PANG — Pangaea Oncology SA Balance Sheet
0.000.00%
- €58.04m
- €58.81m
- €14.27m
- 23
- 17
- 67
- 24
Annual balance sheet for Pangaea Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1.04 | 2.93 | 8.51 | 2.79 | 4.43 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.97 | 4.08 | 4.38 | 6.42 | 7.99 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5.49 | 7.52 | 13.3 | 9.75 | 13.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.553 | 0.429 | 0.353 | 0.545 | 0.901 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 17 | 20.8 | 28.4 | 28.4 | 32.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.68 | 3.18 | 2.72 | 6.86 | 7.01 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.72 | 6.76 | 5.49 | 10.5 | 10.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 8.24 | 14.1 | 22.9 | 18 | 22.1 |
| Total Liabilities & Shareholders' Equity | 17 | 20.8 | 28.4 | 28.4 | 32.4 |
| Total Common Shares Outstanding |